- Home
- REVB vs POLA Comparison
REVB vs POLA Comparison
Compare REVB & POLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- POLA
- Stock Information
- Founded
- REVB 2020
- POLA 1979
- Country
- REVB United States
- POLA United States
- Employees
- REVB N/A
- POLA N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- POLA Industrial Machinery/Components
- Sector
- REVB Health Care
- POLA Miscellaneous
- Exchange
- REVB Nasdaq
- POLA Nasdaq
- Market Cap
- REVB 4.4M
- POLA 5.2M
- IPO Year
- REVB N/A
- POLA 2016
- Fundamental
- Price
- REVB $2.87
- POLA $2.68
- Analyst Decision
- REVB
- POLA
- Analyst Count
- REVB 0
- POLA 0
- Target Price
- REVB N/A
- POLA N/A
- AVG Volume (30 Days)
- REVB 87.7K
- POLA 888.0K
- Earning Date
- REVB 11-07-2025
- POLA 08-14-2025
- Dividend Yield
- REVB N/A
- POLA N/A
- EPS Growth
- REVB N/A
- POLA N/A
- EPS
- REVB N/A
- POLA N/A
- Revenue
- REVB N/A
- POLA $11,967,000.00
- Revenue This Year
- REVB N/A
- POLA N/A
- Revenue Next Year
- REVB N/A
- POLA N/A
- P/E Ratio
- REVB N/A
- POLA N/A
- Revenue Growth
- REVB N/A
- POLA 0.14
- 52 Week Low
- REVB $2.11
- POLA $1.53
- 52 Week High
- REVB $60.48
- POLA $4.69
- Technical
- Relative Strength Index (RSI)
- REVB 56.54
- POLA 66.91
- Support Level
- REVB $2.65
- POLA $2.15
- Resistance Level
- REVB $2.88
- POLA $3.67
- Average True Range (ATR)
- REVB 0.19
- POLA 0.28
- MACD
- REVB 0.03
- POLA 0.09
- Stochastic Oscillator
- REVB 88.00
- POLA 47.62
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About POLA Polar Power Inc.
Polar Power Inc is engaged in designing, manufacturing, and selling DC power generators, renewable energy, and cooling systems for applications in the telecommunications market and, to a lesser extent, in other markets, including military, electric vehicle, marine, and industrial. The company's products include DC generators, backup DC generators, hybrid power systems, Li-Ion battery systems, Marine DC generators, and others. The company's geographical presence is in the United States, Canada, Australia and South Pacific Islands, Asia, Europe and Middle East, United Kingdom, Other North America, South Africa, and others.